This question gains heightened significance in the context of aging, where the concurrent rise in Tet2 mutation prevalence and liver fibrosis incidence underscores the urgent need to elucidate these mechanisms for potential therapeutic interventions. This evidence concerns the gene TET2 and Hepatic fibrosis.